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In this issue, Rohani et al. (2015) report on the role of macrophage-derived
stromelysin-2 (matrix metalloproteinase (MMP)-10) in promoting the turnover of
extracellular matrix (ECM) during cutaneous wound repair. They provide
evidence that MMP-10 speciﬁcally enhances collagenolytic activity of murine
MMP-13 produced by M2-like macrophages. These results emphasize the
important role of macrophage-derived MMP-10 in regulating tissue remodeling
and scar formation during wound healing.
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Proteolysis in wound healing
Wound healing in the skin is a complex
and a strictly controlled process that
involves interplay between different cell
types. Cutaneous wound repair consists
of temporally overlapping, but function-
ally and histologically distinct, phases––
i.e., hemostasis, an inﬂammatory
response, re-epithelization, granulation
tissue formation, and tissue remodeling––
all of which require precise communica-
tion among the various cell types. The
resolution of inﬂammation is an impor-
tant event in normal wound repair, and
failure in this results in persistent inﬂam-
mation and impaired wound closure
(Eming et al., 2007). Subsequently,
activation and differentiation of ﬁbro-
blasts to collagen-producing, α-smooth
muscle actin-positive myoﬁbroblasts
result in the formation of collagen-rich
granulation tissue, which provides
tensile strength to the healing wound.
Finally, wound contraction and remo-
deling and resolution of the granulation
tissue ECM by proteolysis and endo-
cytosis take place, resulting in the
restoration of structure and function of
the skin, with minimal scar formation
(Toriseva and Kähäri, 2009). Failure
in this controlled turnover of deposited
ECM may result in excessive scar
formation.
MMPs are among the major proteolytic
enzymes produced and activated by a
variety of cells participating in cutaneous
wound repair. MMPs are extracellular
endopeptidases, which can be classiﬁed
into distinct subgroups according to their
substrate speciﬁcity. In intact skin, the
production of MMPs is in general low,
but injury to the skin results in a rapid
increase in the production of MMPs.
Accordingly, several MMPs are expressed
in adult human wound tissue, including
collagenase-1 (MMP-1), collagenase-2
(MMP-8), gelatinase-A (MMP-2),
gelatinase-B (MMP-9), membrane type 1
MMP (MMP-14), MMP-19, MMP-26,
MMP-28, stromelysin-1 (MMP-3), and
stromelysin-2 (MMP-10). MMPs can
cleave ECM components, releasing bio-
logically active peptide fragments. In
addition, they are able to process several
nonmatrix substrates––e.g., growth factors
embedded in the ECM or growth factor
receptors on cell surfaces (Nissinen
and Kähäri, 2014). Furthermore, MMPs
have an important role in tissue repair
by promoting the resolution of the
granulation tissue and collagenous scar.
However, the functions of speciﬁc MMPs
in wound healing and tissue ﬁbrosis are
not fully understood.
In this issue, Rohani et al. (2015) have
examined the role of macrophage-
derived MMP-10 during cutaneous
wound healing in a mouse model.
Previously, the expression of MMP-10
had been documented to occur in
migrating keratinocytes at the leading
edge of human and mouse cutaneous
wounds (Saarialho-Kere et al., 1992;
Rechardt et al., 2000). In addition,
expression of active mutant of
MMP-10 in keratinocytes of transgenic
mice resulted in impaired organization
of the wound epithelium, thus providing
mechanistic evidence for the role of
MMP-10 in keratinocyte migration
(Krampert et al., 2004).
Collagenases in wound repair
Collagenases (MMP-1, -8, and -13) are
the principal secreted proteinases cap-
able of cleaving native ﬁbrillar col-
lagens of types I, II, III, V, and IX. Two
mouse counterparts of human MMP-1
have been identiﬁed, Mcol1-A and
Mcol1-B, but only Mcol1-A can cleave
ﬁbrillar collagens (Balbín et al., 2001).
Murine MMP-13 shows the highest
homology with human MMP-13. How-
ever, murine MMP-13 and human
MMP-1 are expressed in similar settings,
including wound repair, indicating that
mouse MMP-13 is a functional homolog
of human MMP-1.
Collagenases identiﬁed in normally
healing human cutaneous wounds are
MMP-1 and MMP-8 (Saarialho-Kere
et al., 1992; Inoue et al., 1995;
Nwomeh et al., 1999). MMP-1 is
expressed by migrating keratinocytes at
the edge of human wounds, and the
activity of MMP-1 is required for migra-
tion of keratinocytes on native type I
collagen (Saarialho-Kere et al., 1992;
Pilcher et al., 1997). Notably, MMP-1 is
expressed by same cells in wound
edges as is MMP-10 (Saarialho-Kere
et al., 1994). MMP-1 is also expressed
by ﬁbroblasts in granulation tissue dur-
ing wound healing, and it is involved in
remodeling of wound collagen. MMP-8
is mainly stored in secretory granules of
neutrophils and released upon activa-
tion of these cells. Mice lacking MMP-8
show impaired re-epithelization and
delayed wound healing, associated
with persistent inﬂammation and a lag
in neutrophil inﬁltration (Gutiérrez-
See related article on pg 2377COMMENTARY
1Department of Dermatology, University of Turku, Turku, Finland; 2Department of Dermatology, Turku
University Hospital, Turku, Finland and 3MediCity Research Laboratory, University of Turku, Turku, Finland
Correspondence: Veli-Matti Kähäri, Department of Dermatology, University of Turku, POB 52, FI-20521
Turku, Finland. E-mail: veli-matti.kahari@utu.ﬁ
2350 Journal of Investigative Dermatology (2015), Volume 135 © 2015 The Society for Investigative Dermatology
Fernández et al., 2007). Adenoviral deli-
very of MMP-8 gene into the liver has
been shown to reverse tissue ﬁbrosis in a
rat model of liver cirrhosis, suggesting a
role for MMP-8 in resolution of tissue
ﬁbrosis (Siller-López et al., 2004).
In murine skin wounds, mouse
MMP-13 shows a similar expression
pattern as does MMP-1 in human wounds.
However, expression of MMP-13 is not
detected in normally healing adult human
wounds, but in chronic cutaneous ulcers
the expression of MMP-13 by ﬁbroblasts
has been documented (Vaalamo et al.,
1997). On the other hand, MMP-13 is
expressed by ﬁbroblasts in fetal skin and
gingival wounds, two types of wounds
that have been characterized by scarless
wound repair (Ravanti et al., 1999, 2001).
Studies with MMP-13-null mice have
shown that murine MMP-13 has a role
in keratinocyte migration, vascularization,
granulation tissue formation, and wound
contraction (Hattori et al., 2009; Toriseva
et al., 2012). Evidence for the anti-ﬁbrotic
role of MMP-13 has been studied in
rodent models of tissue ﬁbrosis. Studies
with MMP-13-null mice suggest that
MMP-13 exhibits anti-ﬁbrotic properties
in murine hepatic ﬁbrosis (Fallowﬁeld
et al., 2007). In addition, adenoviral deli-
very of MMP-13 has been shown to
promoting resolution of hepatic ﬁbrosis
(Endo et al., 2011).
Macrophages in wound healing
Following cutaneous wounding, circu-
lating monocytes migrate to the site of
injury and differentiate into macro-
phages. In general, macrophages have
a role in all phases of wound healing,
and depletion of macrophages results
in delayed wound repair, reduced
granulation tissue formation, and
delayed re-epithelialization and scar
deposition (Lucas et al., 2010). Func-
tional phenotypes of macrophages in
injured skin can be divided into two
distinct subgroups––i.e., the classically
activated M1 subtype and alternatively
activated M2 macrophages (Mantovani
et al., 2002). Several mediators, such
as bacterial lipopolysaccharide, and
inﬂammatory cytokines can stimulate
macrophages to differentiate into M1
macrophages that include antimicrobial
properties (Mosser and Edwards, 2008).
IL-4 and IL-13 induce differentiation to
M2 macrophages, which have an
important role in the later phase
of wound healing when clearance of
ECM and new tissue formation take
place (Mahdavian Delavary et al.,
2011). These cytokines also induce the
expression of MMP-13 in macrophages.
Furthermore, upon phagocytosis of
apoptotic cells, M1 macrophages may
revert to M2 macrophages and contri-
bute to the resolution of inﬂammation
by clearing senescent cells and cellular
debris (Mahdavian Delavary et al.,
2011). M2 macrophages also produce
transforming growth factor-β, and, they
may in this way promote various aspects
of wound healing, such as ﬁbroblast
chemotaxis, angiogenesis, ECM deposi-
tion, and wound contraction. Studies
with macrophage-depleted mice also
demonstrate impaired turnover of gran-
ulation tissue, resulting in scar formation
(Brancato and Albina, 2011; Mahdavian
Delavary et al., 2011).
In this issue, Rohani et al. (2015)
report increased scar formation in
wounded skin of MMP-10-null mice
due to reduced collagenolytic activity.
Furthermore, their data show that the
number of macrophages was not
decreased nor was the migration rate
of macrophages affected in the
MMP-10-deﬁcient mice. However, in
the wounds of MMP-10-null mice, the
production and activity of MMP-13
produced by macrophages was
reduced, resulting in impaired scar
resolution in the wounds. These results
provide novel mechanistic evidence for
an important role for MMP-10 in
regulating the collagenolytic activity of
alternatively activated M2 macrophages
that are responsible for scar resolution
during cutaneous wound repair.
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Playing Polo-Like Kinase in
NRAS-Mutant Melanoma
Hsin-Yi Chen1 and Jessie Villanueva1
NRAS-mutant melanomas are extremely aggressive and highly resistant to
currently available therapeutic modalities. Hence, new targets and therapeutic
strategies for NRAS-driven melanomas are needed. As blocking NRAS directly
has not been possible thus far, targeting downstream NRAS effectors, such as
MAPK/ERK kinase (MEK), is being evaluated as an alternative therapeutic
approach. However, blocking this pathway alone has limited efﬁcacy. In this
issue, Posch et al. report on a combination approach co-targeting polo-like
kinase 1 and MEK in NRAS-mutant melanomas. This combination triggers a dual
blockade of the cell cycle machinery, leading to apoptosis, and providing a new
strategy to treat NRAS-mutant melanoma.
Journal of Investigative Dermatology (2015) 135, 2352–2355. doi:10.1038/jid.2015.253
Mutant-NRAS in melanoma
RAS is mutated in approximately 30% of
human cancers. For example, neoplasms
of the skin, pancreas, and urinary tract
carry activating mutations in the RAS
isoforms NRAS, KRAS, and HRAS, respec-
tively (Prior et al., 2012). In melanoma,
approximately 25% of tumors harbor
NRAS mutations. Most NRAS muta-
tions affect codon 61, locking the small
G protein in the active guanosine
triphosphate-bound form and leading to
persistent RAS signaling (Ascierto et al.,
2013; Burd et al., 2014). Oncogenic
NRAS activates several signaling path-
ways, including the mitogen-activating
protein kinase (MAPK), PI3K/mTOR,
and Ral GDP dissociation stimulator
(RalGDS), resulting in aberrant cell pro-
liferation and increased tumor cell survi-
val. Attempts to inhibit oncogenic NRAS
directly have not been successful to date,
prompting a search for alternative strate-
gies to blunt NRAS signaling. Suppression
of the NRAS effector pathway MAPK
(RAF/MEK/ERK) with MEK (MAPK/ERK
kinase) inhibitors (MEKi) has been eval-
uated in clinical trials of NRAS-mutant
melanoma; however, response rates
were barely 20% and short-lived
(Ascierto et al., 2013). Immune check-
point inhibitors are only approved for
BRAF-mutant patients thus far, and their
role in treating NRAS-mutant melanoma
remains to be established. Additionally, it
has been reported recently that NRAS-
mutant melanomas are associated with
lower levels of lymphocyte inﬁltration,
suggesting a more immunosuppressive
microenvironment and possibly poor
responses to immunotherapy (Thomas
et al., 2015). Consequently, identifying
novel targets and/or co-targeting other
NRAS-speciﬁc vulnerabilities are essential
for designing effective treatments for these
types of tumors. In this issue of the Journal
of Investigative Dermatology, Posch et al.
(2015) report on suppressing a mitotic
master Ser/Thr kinase, polo-like kinase 1
(PLK1) in combination with MEK inhibi-
tion as a therapeutic strategy for NRAS-
mutant melanoma (Figure 1; Posch et al.,
2015).
Polo-like kinase: a new therapeutic target
for NRAS-mutant melanoma
PLK1 has emerged as a therapeutic
target in cancer as it regulates cell cycle
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